Skip to Content
Merck
  • Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study.

Development and validation of an UFLC-MS/MS method for enantioselectivity determination of d,l-thero-methylphenidate, d,l-thero-ethylphenidate and d,l-thero-ritalinic acid in rat plasma and its application to pharmacokinetic study.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2016-01-12)
Chenghao Zhang, Huafei Luo, Yubo Wu, Junyun Zhang, Furong Zhang, Guobei Lin, Hao Wang
ABSTRACT

A chiral UFLC-MS/MS method was established and validated for quantifying d-threo-methylphenidate (d-threo-MPH), l-threo-methylphenidate (l-threo-MPH), d-threo-ethylphenidate (d-threo-EPH), l-threo-ethylphenidate (l-threo-EPH) and d,l-threo-ritalinic acid (d,l-threo-RA) in rat plasma over the linearity range of 1-500ng/mL. Chiral separation was performed on an Astec Chirobiotic V2 column (5μm, 250×2.1mm) with isocratic elution using methanol containing 0.003% ammonium acetate (w/v) and 0.003% trifluoroacetic acid (v/v) at a flow of 0.3mL/min. All analytes and IS were extracted from rat plasma by a one-step liquid-liquid extraction (LLE) method. The intra- and inter-run accuracies were within 85-115%, and the intra- and inter-run precision were <10% for all analytes. Extraction recoveries were 55-62% for d-threo-MPH, 54-60% for l-threo-MPH, 55-60% for d-threo-EPH, 53-57% for l-threo-EPH and 25-30% for d,l-threo-RA. The validated UFLC-MS/MS method successfully applied to the pharmacokinetic interaction study of oral d-threo-MPH and l-threo-MPH (alone or in combination) in female Sprague Dawley rats. The EPH was not detected in rat plasma following oral administrated MPH without EtOH. As far as it is known to the authors, this study is the first one step liquid-liquid extraction method to extract and UFLC-MS/MS method to quantify d-threo-MPH, l-threo-MPH, d-threo-EPH, l-threo-EPH and d,l-threo-RA simultaneously.

MATERIALS
Product Number
Brand
Product Description

Supelco
Astec® CHIROBIOTIC® V Chiral HPLC Column, 5 μm particle size, L × I.D. 10 cm × 4.6 mm
Supelco
Astec® CHIROBIOTIC® V2 Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 21.2 mm
Supelco
Astec® CHIROBIOTIC® V2 Chiral HPLC Column, 5 μm particle size, L × I.D. 10 cm × 2.1 mm
Supelco
Astec® CHIROBIOTIC® V2 Chiral HPLC Column, 5 μm particle size, L × I.D. 10 cm × 4.6 mm
Supelco
Astec® CHIROBIOTIC® V Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
Supelco
Astec® CHIROBIOTIC® V2 Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 2.1 mm
Supelco
Astec® CHIROBIOTIC® V2 Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
Supelco
Astec® CHIROBIOTIC® V Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm
Supelco
Astec® CHIROBIOTIC® V2 Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 2.1 mm
Supelco
Astec® CHIROBIOTIC® V Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 2.1 mm
Supelco
Astec® CHIROBIOTIC® V Chiral HPLC Column, 5 μm particle size, L × I.D. 10 cm × 2.1 mm
Supelco
Astec® CHIROBIOTIC® V2 Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm
Supelco
Astec® CHIROBIOTIC® V Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 2.1 mm
Supelco
Astec® CHIROBIOTIC® V2 Chiral HPLC Guard Column, Cartridge, 5 μm particle size, L × I.D. 2 cm × 4 mm
Supelco
Astec® CHIROBIOTIC® V Chiral HPLC Guard Column, Cartridge, 5 μm particle size, L × I.D. 2 cm × 4 mm